Telomir Pharmaceuticals, Inc.
TELO
$1.45
-$0.05-3.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.03M | 1.85M | 2.64M | 5.38M | 879.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.07M | 2.19M | 2.91M | 6.01M | 1.47M |
| Operating Income | -5.07M | -2.19M | -2.91M | -6.01M | -1.47M |
| Income Before Tax | -5.07M | -2.18M | -2.90M | -5.99M | -1.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.07M | -2.18M | -2.90M | -5.99M | -1.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.07M | -2.18M | -2.90M | -5.99M | -1.45M |
| EBIT | -5.07M | -2.19M | -2.91M | -6.01M | -1.47M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.17 | -0.07 | -0.10 | -0.20 | -0.05 |
| Normalized Basic EPS | -0.11 | -0.05 | -0.06 | -0.13 | -0.03 |
| EPS Diluted | -0.17 | -0.07 | -0.10 | -0.20 | -0.05 |
| Normalized Diluted EPS | -0.11 | -0.05 | -0.06 | -0.13 | -0.03 |
| Average Basic Shares Outstanding | 30.01M | 29.76M | 29.66M | 29.61M | 29.61M |
| Average Diluted Shares Outstanding | 30.01M | 29.76M | 29.66M | 29.61M | 29.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |